Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

On June 23, Eli Lilly and Company (NYSE:LLY) declared a quarterly dividend of $1.50 per share, which was in line with its ...

Here's how Eli Lilly compares to Johnson & Johnson and Becton, Dickinson, a couple of top healthcare stocks with dividend growth streaks of more than 50 years.

Alzheimer's Disease Treatments: With the recent approval of donanemab, Eli Lilly is well-positioned in the Alzheimer's disease space, a market with significant unmet needs and growth potential.

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

Eli Lilly (NYSE: LLY) may seem like an expensive stock to invest in right now. Its $720 billion market capitalization also means it's the most valuable healthcare stock in the world. It's one that ...

Moreover, Eli Lilly’s stock performance has sparked speculation about a potential split, though its last split occurred in 1997. So, there are plenty of potential catalysts ahead.

JPMorgan said Eli Lilly is enrolling about 500,000 new obesity drug patients per month, and maintains more than 60% share in ...

Eli Lilly & Co. closed 20.65% short of its 52-week high of $972.53, which the company achieved on August 22nd.

The stock's fall snapped a four-day winning streak.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Eli Lilly's sales and profit growth has been impressive Eli Lilly has a solid roster of products in its portfolio already, with Mounjaro and Zepbound leading the charge.